SAMHSA Had to Write a Letter Confirming Naloxone Isn't 'Harm Reduction' — to Keep It Funded

On July 29, the Substance Abuse and Mental Health Services Administration sent grantees a “Dear Colleague” letter — the federal government’s version of a memo clarifying a rule before someone gets penalized for misreading it. The clarification: distributing naloxone, the medication that reverses opioid overdoses, does not count as a “harm reduction activity” under current federal policy.

Read that twice. The single most consensus, least controversial intervention in the entire overdose response — a drug that does nothing but block an opioid overdose in progress, with no abuse potential, no downside, no “controversial” use case — needed a formal carve-out from a category it obviously, definitionally belongs to.

THE TAKE: When an agency has to define its most uncontroversial tool out of the box that political pressure has made toxic, that’s not clarity — it’s the label being broken, not the medicine.

Here’s the plain-language version. “Harm reduction” has become a contested phrase in some federal and state funding contexts — grantees whose syringe-service programs, drug-checking supplies, or broader harm-reduction line items live under that label have watched funding scrutiny and restrictions tighten around it. A “harm reduction activity” classification, in grant terms, determines which funding streams a program can draw from and which ones get flagged for review. By ruling naloxone distribution outside that classification, SAMHSA effectively insulated it from a fight the word “harm reduction” is currently losing in some rooms. The more than $281 million in funding opportunities SAMHSA announced July 6 — and the $11 million specifically earmarked for community overdose-prevention grants expanding access to FDA-approved reversal medications — sits on the safe side of that line as a result.

That’s a win for the dollars. It’s also an indictment of the process: a life-saving medication needed a bureaucratic workaround to avoid being collateral damage in a fight about vocabulary. Programs doing harm reduction work beyond naloxone — the syringe access, the fentanyl test strips, the drug-checking — don’t get the same exemption. They’re still standing in the blast radius the letter carved naloxone out of.

None of that changes what’s true for you, right now, today. Naloxone is still legal. It’s still funded — more explicitly than almost anything else in this letter. You can still get it over the counter at a pharmacy, free from most health departments, free from most opioid treatment and syringe programs, no prescription, no ID check, no judgment required. A reclassification memo in a federal filing cabinet doesn’t touch that. It’s still yours. Go get it, and keep it somewhere you can reach in the dark.